Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells

Authors:

Abstract
Effective immune checkpoint blockades have improved the overall survival of patients with metastatic melanoma. The monoclonal antibody nivolumab blocks programmed cell death 1 (PD-1), an inhibitory immune checkpoint receptor expressed on activated T cells and B cells. Nivolumab is associated with a significant improvement in overall survival and progression-free survival and associated with a low risk of high-grade toxic effects [1]. Recent studies, however, showed that the immune activation caused by PD-1 blockade might promote severe autoimmune toxicity [2].